U.S. License Holder:
Sicor Biotech (Teva)
Date of License:
August-29-2012
Last Update:
Oct-23-2024
FDA-Approved Indications
GRANIX (tbo-filgrastim) is a leukocyte growth factor indicated in adult and pediatric patients 1 month and older for reduction in the duration of severe neutropenia in patients with non-myeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia.